L3VLUP
ProSign in

TAK in the 13F filings

Takeda Pharmaceutical Co Ltd · CUSIP 874060205

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Sep 2025
the date the book describes
Filed
13 Nov 2025
latest of these filings; the earliest 13 Nov 2025
Managers listing it
2
at least, of 95 tracked, among listed positions
Comparable managers
95
filed both Q2 2025 and Q3 2025; 2 listed it in both
Shares listed
17,268,729
combined, among listed positions
Reported value
$253m
combined, at the quarter end

Among the 95 comparable managers: 2 buyers (opened or added shares) and 0 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +673,956.

Managers listing TAK in Q3 2025

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2025, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

2 of 2 holders

ActionFiling
Capital Research Global Investors13,404,129$196munder 0.1%Added+108,55613 Nov 2025 (the filing on sec.gov)
Renaissance Technologies LLC3,864,600$57m0.07%Added+565,40013 Nov 2025 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2025 to Q3 2025, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q3 2024 to 3 in Q2 2026

Tracked managers listing it, at least.

0510152019202020212023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
TAK by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20183$83mn.a.n.a.
Q1 201912$1.2bnn.a.n.a.
Q2 20196$721mn.a.n.a.
Q3 20199$718mn.a.n.a.
Q4 20196$645mn.a.n.a.
Q1 20204$362mn.a.n.a.
Q2 20204$395mn.a.n.a.
Q3 20204$423mn.a.n.a.
Q4 20205$549mn.a.n.a.
Q1 20214$699mn.a.n.a.
Q2 20214$476mn.a.n.a.
Q3 20214$410mn.a.n.a.
Q4 20212$111mn.a.n.a.
Q2 20223$69mn.a.n.a.
Q3 20223$68mn.a.n.a.
Q4 20225$208mn.a.n.a.
Q1 20235$349mn.a.n.a.
Q2 20235$353mn.a.n.a.
Q3 20234$311mn.a.n.a.
Q4 20235$374m41
Q1 20243$228m02
Q2 20244$243m31
Q3 20243$236m21
Q4 20243$271m12
Q1 20253$256m30
Q2 20252$257m20
Q3 20252$253m20
Q4 20254$355m118
Q1 20263$467m137
Q2 20263$410m1310

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

TAK and LLY →TAK and JNJ →TAK and VRTX →Choose a stock to compare with TAK →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own TAK, latest filings →Back to the 13F Explorer →